Mei-Yin Polley
波利梅银
PhD
Professor of Public Health Sciences, Biostatistics公共卫生科学与生物统计学教授
👥Biography 个人简介
Mei-Yin Polley is a biostatistician and global cancer researcher specializing in Asia-Pacific cancer epidemiology and adaptive clinical trial design. Her work improves cancer clinical trial methodology across international settings and addresses cancer disparities in Asian populations.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Adaptive Clinical Trial Design
Developed novel adaptive enrichment and seamless phase II/III trial designs used in global oncology trials, improving efficiency for cancer drug development.
Asia-Pacific Cancer Disparities
Led epidemiological studies quantifying cancer incidence and survival disparities across Asian and Pacific populations, informing targeted prevention programs.
Biomarker-Stratified Trial Methods
Advanced statistical frameworks for biomarker-driven oncology trials, enabling precision medicine approaches in international multi-center settings.
Representative Works 代表性著作
Statistical design considerations for cancer biomarker studies
Journal of the National Cancer Institute (2020)
Methodological guidance for designing statistically rigorous biomarker-stratified cancer studies applicable across international trial settings.
Cancer incidence trends in Asian Americans: Implications for prevention
Cancer Epidemiology, Biomarkers & Prevention (2019)
Analysis of cancer incidence trends in Asian-American subpopulations revealing distinct patterns requiring culturally tailored interventions.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Richard Sullivan
King's College London
Freddie Bray
International Agency for Research on Cancer (IARC)
David Watkins
University of Washington
Sharmila Anandasabapathy
Weill Cornell Medicine
关注 波利梅银 的研究动态
Follow Mei-Yin Polley's research updates
留下邮箱，当我们发布与 Mei-Yin Polley（University of Chicago）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment